Abstract
ABSTRACT
Diabetes mellitus is well_known for the heavy economical burden it poses on society. The DiabCOST study was conducted to estimate the direct medical costs of DM in the adult population in Turkey. From 13 participating centers, a total of 959 diabetic patients were included. Investigators enrolled every diabetic patient encountered in the wards or outpatient clinics of their center during a period of 2 months. Demographical, medical and economical data collection included the 2-month study period as well as the preceding 12 months. The great majority of patients (89.9%) had type II DM, While 97 (10.1%) had type I disease. The patient population was characterized by high systemic complication rates and poor glycemic control. A total of 672 patients (70.1%) had one or more systemic complications. The annual direct cost per patient was found to be between 1100-2100 dollars .About half of this amount was due to treatment costs (560-1100 dollars). For the patients with diabetic complications, total direct cost was approximately 3 times the cost of those without. Total direct cost increased 6.5-fold when a patient was hospitalized. Oral hypoglycemic, insulin and combined insulin and oral hypoglycemic treatments cost respectively 2.5,3 and 4 times more than diet alone. As the study is conducted in tertiary health care facilities, the observed complication rate may not accurately reflect the Turkish population. We have therefore employed a range of 0-70% as the rate of diabetic complications. With this model, the overall direct cost of DM in Turkey may be estimated to be 1-2.5 billion USD per year, each 10% increment in the complication rate resulting in an additional cost of 180-190 million USD annually.
Diabetes mellitus is well_known for the heavy economical burden it poses on society. The DiabCOST study was conducted to estimate the direct medical costs of DM in the adult population in Turkey. From 13 participating centers, a total of 959 diabetic patients were included. Investigators enrolled every diabetic patient encountered in the wards or outpatient clinics of their center during a period of 2 months. Demographical, medical and economical data collection included the 2-month study period as well as the preceding 12 months. The great majority of patients (89.9%) had type II DM, While 97 (10.1%) had type I disease. The patient population was characterized by high systemic complication rates and poor glycemic control. A total of 672 patients (70.1%) had one or more systemic complications. The annual direct cost per patient was found to be between 1100-2100 dollars .About half of this amount was due to treatment costs (560-1100 dollars). For the patients with diabetic complications, total direct cost was approximately 3 times the cost of those without. Total direct cost increased 6.5-fold when a patient was hospitalized. Oral hypoglycemic, insulin and combined insulin and oral hypoglycemic treatments cost respectively 2.5,3 and 4 times more than diet alone. As the study is conducted in tertiary health care facilities, the observed complication rate may not accurately reflect the Turkish population. We have therefore employed a range of 0-70% as the rate of diabetic complications. With this model, the overall direct cost of DM in Turkey may be estimated to be 1-2.5 billion USD per year, each 10% increment in the complication rate resulting in an additional cost of 180-190 million USD annually.
Article Info
Published In
Journal
Endocrinology Research and Practice
Volume / Issue
Volume 2 · Issue 1
Pages
-
History
Published Online
March 17, 2022
Copyright
Copyright (c) 1998 Endocrinology Research and Practice
Affiliations
H. Erdal Akalın
Pfizer Pharmaceuticals Inc
Cem Koçkar
Department of Internal Medicine, Division of Endocrinology, Cerrahpaşa Medical Faculty, University of Istanbul, Cerrahpaşa, Turkey
Kubilay Karşıdağ
Istanbul University Istanbul Medical Faculty, Department of Internal Medicine, Division of Diabetes, Istanbul, Turkey
Nilgün Gürsoy
Uludağ University School of Medicine, Department of Endocrinology and Metabolism, Bursa, Turkey
Alper Gürlek
Hacettepe University, School of Medicine, Departtment of Endocrinology and Metabolism, Ankara, Turkey
Serdar Güler
Ankara Numune Education and Research Hospital, Department of Endocrinology and Metabolism Diseases, Ankara
Murat Erdoğan
Ankara University, School of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey
Şevki Çetinkalp
Ege University Medical School, Division of Endocrinology and Metabolism, Izmir, Turkey
Ömer Azal
Department of Internal Medicine, Division of Endocrinology, Cerrahpaşa Medical Faculty, University of Istanbul, Cerrahpaşa, Turkey
Göksun Ayvaz
Gazi University, Medical Faculty, Department of Endocrinology and Metabolism, Ankara, Turkey
Neslihan Aydın
Department of Internal Medicine, Division of Endocrinology, Cerrahpaşa Medical Faculty, University of Istanbul, Cerrahpaşa, Turkey
Özer Açbay
Department of Internal Medicine, Division of Endocrinology, Cerrahpaşa Medical Faculty, University of Istanbul, Cerrahpaşa, Turkey
Oktay Özdemir
Omega Contract Research Organization
Murat Hayran
Omega Contract Research Organization
Aytekin Oğuz
Goztepe Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Cite this Article
Akalın, H. E., Koçkar, C., Karşıdağ, K., Gürsoy, N., Gürlek, A., Güler, S., … Oğuz, A. (2022). Direct Medical Cost Analysis in Patients with Diabetes Mellitus in Turkey: Diabcost . Endocrinology Research and Practice, 2(1), -. Retrieved from https://endocrinolrespract.org/index.php/pub/article/view/27
Outlines